Neovascular Glaucoma Clinical Trial
Official title:
Evaluation of Effectiveness of KDR2-2 Suspension Eyedrop on Neovascular Regression in the Treatment of Neovascular Glaucoma: an Exploratory Clinical Trial
The clinical trial is aimed to evaluate the anti-neovascular effect of KDR2-2 suspension eyedrop in the treatment of neovascular glaucoma. Fourty subjects would receive either 0.96 or 3.84 mg/per day/eye, in a QID fashion, ×7 days (those without complications can continue to 28 days). The anti-neovascular effect of KDR2-2 on iris neovascularization would be evaluated at day 1, day 7, day 14, day 28 after KDR2-2 usage.
Neovascular glaucoma (NVG) has a high blinding rate and poor prognosis. Anti-glaucoma surgery is the main stake of saving visual function and relieving pain, but the proliferation of iris neovascularization (NVI) makes it difficult to treat NVG. Normally, the patients need an intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents prior to glaucoma surgery to control the NVI proliferation. KDR2-2, a novel small-molecule tyrosine kinase inhibitor targeting VEGF receptor 2 (VEGFR2), has demonstrated anti-neovascular effect without obvious side-effects or complications in animal studies and a Phase I clinical trial (NCT04620109). In this study, 40 patients with NVG will be included to evaluate the effectiveness of KDR2-2 suspension eyedrop on NVI in NVG eyes. The included subjects would receive either 0.96 or 3.84 mg/day/eye, in a QID fashion, ×7 days (those without complications can continue to 28 days). This study aims to and propose a novel, non-invasive and more compliant method for the treatment of NVG. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00491712 -
Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection
|
N/A | |
| Recruiting |
NCT04519619 -
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
|
||
| Completed |
NCT01370135 -
Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma
|
N/A | |
| Completed |
NCT04970251 -
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
|
N/A | |
| Completed |
NCT02805257 -
Ahmed Glaucoma Valve Surgery With Mitomycin-C
|
Phase 2 | |
| Recruiting |
NCT02067013 -
Analysis of Aqueous and Vitreous Humor
|
Phase 2 | |
| Completed |
NCT00524758 -
Oculusgen (Ologen) Glaucoma MMC Control in Estonia
|
Phase 3 | |
| Withdrawn |
NCT00727038 -
Lucentis for New Onset Neovascular Glaucoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02947867 -
Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
|
Phase 2/Phase 3 | |
| Completed |
NCT01711879 -
Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
|
N/A | |
| Terminated |
NCT02260219 -
Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma
|
N/A | |
| Withdrawn |
NCT00441181 -
Effects of Travoprost on Neovascular Glaucoma
|
N/A | |
| Completed |
NCT01051583 -
Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma
|
Phase 2 | |
| Completed |
NCT05156021 -
A Study on the Treatment Strategy of NVG Secondary to PDR
|
N/A | |
| Terminated |
NCT01301378 -
Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
|
N/A | |
| Not yet recruiting |
NCT05316142 -
Any Unique Identifier Assigned to the Protocol by the Sponsor
|
N/A | |
| Completed |
NCT03154892 -
The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
|
N/A |